Kimedi explains to SanofiGenzyme’s sales representatives the structure, application and benefits of the diagnostic system. From now on, the sales representatives will promote the use of the diagnostic system in doctors’ practices and other medical institutions throughout Germany.
Thanks to the support of Prof. Dr. med. Simone Spuler, a field trial at theUniversity ambulance clinic for neuromuscular diseases of the Charité in Berlin-Buch. Valuable new insights into the use of the Q46 questionnaires for neuromuscular diseases were gained. In all 4 of the diagnosed Pompe disease patients, whose diagnosis we did not know […]
The software developers of NeuroSys and KImedi worked closely together during the summer months to integrate Kimedi’s ai-engine into NeuroSys’ PatientConcept App. This means that the questionnaires are now available to a broad user group of patients and physicians.
The new project for early detection of the rare disease “Morbus Pompe” is generously supported by the pharmaceutical company SanofiGenzyme GmbH and the software company NeuroSys GmbH for 2 years.
Common pre-diagnostic features in individuals with different rare diseases represent a key for diagnostic support with computerized pattern recognition? [Download]